Trials / Unknown
UnknownNCT03758144
Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes
Rifaximin Improves Insulin Resistance in Metabolic Syndrome and Reduces Insulin Requirement in Type 2 Diabetes
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- Zagazig University · Other Government
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Gut Dysbiosis had been involved in some way in the pathogenesis of some extra-intestinal disorders including metabolic syndrome, cardiovascular disease, and obesity.
Detailed description
Accumulating evidence had linked metabolic syndrome and diabetes to dysequilibrium in gut microbiota, which are a critical regulator of host metabolism and immune responses. gut microbiota interacts with host signaling pathways, leading to modulation of the endocrine system, immune responses. gut microbial metabolites, in particular, short-chain fatty acids, have been significantly associated with liability to diabetes. patients with positive fecal short-chain fatty acids will be given rifaximin
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rifaximin 200 MG | patients with type 2 diabetes and gut dysbiosis will be given rifaximin |
Timeline
- Start date
- 2018-11-01
- Primary completion
- 2019-06-01
- Completion
- 2019-07-01
- First posted
- 2018-11-29
- Last updated
- 2018-11-29
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT03758144. Inclusion in this directory is not an endorsement.